Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bazedoxifene in Metastatic Pancreatic Adenocarcinoma
NCT04812808Unknown
- Sponsor
- Hôpital Fribourgeois
- Start
- Feb 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of bazedoxifene in pancreatic adenocarcinoma (PDAC), sponsored by Hôpital Fribourgeois. Primary endpoint: Change in IL-6/GP-130/STAT3 pathway expression at 3 months. Status: unknown.
02
Drugs
bazedoxifene
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04812808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04812808.